siRNA RIP3

siRNA / miRNA gene silencing Human - MIA PaCa-2 RIP3

Experiment
siRNA / miRNA gene silencing Human - MIA PaCa-2 RIP3
Product
siRNA RIP3 from Santa Cruz Biotechnology
Manufacturer
Santa Cruz Biotechnology

Protocol tips

Protocol tips
Add diluted siRNA to diluted Lipofectamine® RNAiMAX Reagent (1:1 ratio). 

Incubate for 5 minutes at room temperature and add to cells. 

Incubate cells for 3 days at 37°C

Publication protocol

Transfection of siRNA was performed using Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s instructions. RIP3 siRNA (sc-61482) was purchased from Santa Cruz Biotechnology. The control siRNA (6568) was purchased from Cell Signaling Technology. Three days after siRNA transfection, the cells were used for subsequent experiments.

Full paper   Login or join for free to view the full paper.

Reviews

siRNA RIP3 from Santa Cruz Biotechnology has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing siRNA / miRNA gene silencing Human - MIA PaCa-2 RIP3 using siRNA RIP3 from Santa Cruz Biotechnology.

View full paper   Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Santa Cruz Biotechnology for siRNA RIP3 below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing siRNA / miRNA gene silencing Human - MIA PaCa-2 RIP3 using siRNA RIP3 from Santa Cruz Biotechnology. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms